Legesse, B., Babadi, B., & Forester, B. (2017).

Management of Neuropsychiatric
Symptoms in Neurocognitive Disorders. Focus (American Psychiatric Publishing), 15(1),
18–25. https://doi.org/10.1176/appi.focus.20160031

Summary - Acquired deterioration in cognitive and functioning capacities is the

hallmark of dementias, which the DSM-5 renames neurocognitive disorders (NCDs). Mild
NCD, which now includes the prior classification of mild cognitive impairment, is now
part of the DSM-5. The following aetiologies for NCDs are recognised by DSM-5:
Alzheimer's disease-related NCD, vascular NCD, NCD with Lewy bodies, frontotemporal
NCD, substance- or medication-induced NCD, traumatic brain injury-related NCD,
Huntington's disease-related NCD, HIV infection-related NCD, prion disease-related
NCD, and NCD caused by other medical conditions are examples of NCDs. The authors
of this study cover a wide range of therapies that have been researched for the
management and treatment of neuropsychiatric symptoms in NCD patients. Many kinds
of drugs, such as antipsychotics, antidepressants, anticonvulsants, and cholinesterase
inhibitors, have been used in addition to nonpharmacological therapies.

5. Camps, J., García-Heredia, A., Hernández-Aguilera, A., & Joven, J. (2016).

Paraoxonases, mitochondrial dysfunction and non-communicable diseases.
Chemico-biological interactions, 259(Pt B), 382–
387. https://doi.org/10.1016/j.cbi.2016.04.005